Enveric Biosciences to Engage Investors at UBS 3rd Virtual CNS Day
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

Image: Businesswire
Enveric Biosciences, a biotechnology firm specializing in neuroplastogenic therapeutics, will participate in the UBS 3rd Virtual CNS Day on June 15, 2026. The event will feature one-on-one meetings with investors to discuss the company's strategic developments and milestones.
- 01Enveric Biosciences focuses on small-molecule therapeutics for psychiatric and neurological disorders.
- 02The company's lead candidate, EB-003, targets 5-HT2A and 5-HT1B receptors for antidepressant effects.
- 03The UBS 3rd Virtual CNS Day is scheduled for June 15, 2026.
- 04Enveric aims to address unmet needs in mental health without hallucinogenic effects.
- 05The company is advancing its drug discovery platform with a growing library of chemical structures.
Advertisement
In-Article Ad
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company based in Cambridge, Massachusetts, is set to participate in the UBS 3rd Virtual CNS Day on June 15, 2026. The event will facilitate one-on-one meetings between Enveric's management team and registered investors, focusing on the company's business strategies, recent achievements, and future milestones. Enveric is dedicated to developing innovative neuroplastogenic small-molecule therapeutics aimed at treating psychiatric and neurological disorders. Its lead candidate, EB-003, is designed to selectively engage the 5-HT2A and 5-HT1B receptors, providing fast-acting antidepressant and anxiolytic effects without hallucinogenic properties. Enveric's approach leverages a unique drug discovery platform and a diverse library of proprietary chemical structures to advance its therapeutic pipeline. The company emphasizes its commitment to addressing significant unmet needs in mental health care, aiming to enhance patient outcomes through its novel compounds.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about the future of neuroplastogenic therapeutics?
Connecting to poll...
Read the original article
Visit the source for the complete story.





